<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7264541\results\search\disease\results.xml">
  <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
  <result pre="be monitored for up to 15Â days for evidence of" exact="respiratory" post="deterioration. In the absence of validated specific treatment, the"/>
  <result pre="to 15Â days for evidence of respiratory deterioration. In the" exact="absence of" post="validated specific treatment, the primary approach to therapy is"/>
  <result pre="respiratory deterioration. In the absence of validated specific treatment, the" exact="primary" post="approach to therapy is mainly symptomatic and delivery is"/>
  <result pre="validated specific treatment, the primary approach to therapy is mainly" exact="symptomatic" post="and delivery is considered in the event of critical"/>
  <result pre="symptomatic and delivery is considered in the event of critical" exact="respiratory" post="distress in order to maximise oxygenation and lung capacity.3,"/>
  <result pre="4, 5 However, it has been reported that women with" exact="respiratory" post="signs may be given antiviral treatment to improve their"/>
  <result pre="is a novel nucleotide analogue prodrug which incorporates into nascent" exact="viral" post="RNA chains and results in preâ€�mature termination. Its effectiveness"/>
  <result pre="terminal glycosylation of the cellular receptor, angiotensinâ€�converting enzyme 2, block" exact="virus infection." post="(Hydroxy)chloroquine has been used in SARSâ€�CoVâ€�2â€�infected humans with highly"/>
  <result pre="as a cure for patients at each stage of the" exact="disease" post="and as a preventive measure.16, 17, 18, 19 Lopinavir,"/>
  <result pre="and as a preventive measure.16, 17, 18, 19 Lopinavir, a" exact="viral" post="protease inhibitor, with its pharmacological booster ritonavir (LPV/R) is"/>
  <result pre="countries, including China and India, have approved its use in" exact="symptomatic" post="infected patients, although the first randomised, controlled, openâ€�label trial"/>
  <result pre="It has been used for years in the treatment of" exact="chronic hepatitis C." post="Based on its direct antiâ€�viral activity against SARSâ€�CoVâ€�2 in"/>
  <result pre="has been used for years in the treatment of chronic" exact="hepatitis C." post="Based on its direct antiâ€�viral activity against SARSâ€�CoVâ€�2 in"/>
  <result pre="also suggested that chloroquine may also reduce the risk of" exact="viral" post="transplacental transmission to the fetus.29 The optimal dosage to"/>
  <result pre="compared with controls at all three trimesters of pregnancy, including" exact="preterm birth," post="low birthweight and birth defects.31 Significant teratogenic effects have"/>
  <result pre="clinical progression of the disease: to remain asymptomatic or, in" exact="symptomatic" post="patients, to avoid progression to acute respiratory distress syndrome."/>
  <result pre="remain asymptomatic or, in symptomatic patients, to avoid progression to" exact="acute" post="respiratory distress syndrome. In the latter the obstetrician will"/>
  <result pre="asymptomatic or, in symptomatic patients, to avoid progression to acute" exact="respiratory" post="distress syndrome. In the latter the obstetrician will often"/>
  <result pre="management between 25 and 32Â weeksâ€™ remains challenging in the" exact="absence of" post="effective antiviral treatment.2 The second objective should be to"/>
  <result pre="effective antiviral treatment.2 The second objective should be to decrease" exact="viral" post="load and duration of contagiousness in infected pregnant women."/>
  <result pre="in infected pregnant women. The majority do well, but the" exact="infection" post="can disrupt their â€˜obstetrical calendarâ€™. Some procedures need to"/>
  <result pre="calendarâ€™. Some procedures need to be performed at a specific" exact="gestational" post="age, such as screening using firstâ€�trimester serum markers, ultrasound"/>
  <result pre="J Med202010.1056/NEJMc2009316 2PeyronnetV, SibiudeJ, DeruelleP, HuissoudC, LescureX, LucetJâ€�C, et al." exact="Infection" post="par le SARSâ€�CoVâ€�2 chez les femmes enceintes. Ã‰tat des"/>
  <result pre="al. Clinical characteristics and intrauterine vertical transmission potential of COVIDâ€�19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
  <result pre="XiongZ, WangS, LinX, et al. Clinical features and obstetric and" exact="neonatal" post="outcomes of pregnant patients with COVIDâ€�19 in Wuhan, China:"/>
  <result pre="antiviral activity of Remdesivir (GSâ€�5734â&quot;¢) in participants with severe coronavirus" exact="disease" post="(COVIDâ€�19) â€&quot; Full Text View â€&quot; ClinicalTrials.gov [https://clinicaltrials.gov/ct2/show/NCT04292899]. Accessed"/>
  <result pre="antiviral activity of Remdesivir (GSâ€�5734â&quot;¢) in participants with moderate coronavirus" exact="disease" post="(COVIDâ€�19) compared to standard of care treatment â€&quot; Full"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARSâ€�CoVâ€�2). Clin Infect Dis202010.1093/cid/ciaa237 14ColsonP,"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARSâ€�CoVâ€�2). Clin Infect Dis202010.1093/cid/ciaa237 14ColsonP, RolainJâ€�M,"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARSâ€�CoVâ€�2). Clin Infect Dis202010.1093/cid/ciaa237 14ColsonP, RolainJâ€�M, RaoultD."/>
  <result pre="Sci2020;49. 16Hydroxychloroquine, hydroxychloroquine, azithromycin in the treatment of SARS CoVâ€�2" exact="infection" post="â€&quot; Full Text View â€&quot; ClinicalTrials.gov [https://clinicaltrials.gov/ct2/show/NCT04341727]. Accessed 18"/>
  <result pre="19Hydroxychloroquine versus placebo in COVIDâ€�19 patients at risk for severe" exact="disease" post="â€&quot; Full Text View â€&quot; ClinicalTrials.gov [https://clinicaltrials.gov/ct2/show/NCT04325893]. Accessed 18"/>
  <result pre="severity and improve the prognosis of patients with novel coronavirus" exact="disease" post="(COVIDâ€�19). J Intern Med202010.1111/joim.13063 25Lopinavir/Ritonavir, ribavirin and IFNâ€�beta combination"/>
  <result pre="MukadiD, et al. A randomized, controlled trial of ebola virus" exact="disease" post="therapeutics. N Engl J Med2019;381:2293â€&quot;303.31774950 28LevyRA, VilelaVS, CataldoMJ, RamosRC,"/>
  <result pre="VilelaVS, CataldoMJ, RamosRC, DuarteJL, TuraBR, et al. Hydroxychloroquine (HCQ) in" exact="lupus" post="pregnancy: doubleâ€�blind and placeboâ€�controlled study. Lupus2001;10:401â€&quot;4.11434574 29ZhangS, YiC, LiC,"/>
  <result pre="YiC, LiC, ZhangF, PengJ, WangQ, et al. Chloroquine inhibits endosomal" exact="viral" post="RNA release and autophagyâ€�dependent viral replication and effectively prevents"/>
  <result pre="et al. Chloroquine inhibits endosomal viral RNA release and autophagyâ€�dependent" exact="viral" post="replication and effectively prevents maternal to fetal transmission of"/>
  <result pre="WykJ, NortonM. Maternal and foetal outcomes among 4118 women with" exact="HIV infection" post="treated with Lopinavir/Ritonavir during pregnancy: analysis of populationâ€�based surveillance"/>
  <result pre="NortonM. Maternal and foetal outcomes among 4118 women with HIV" exact="infection" post="treated with Lopinavir/Ritonavir during pregnancy: analysis of populationâ€�based surveillance"/>
  <result pre="data from the national study of HIV in pregnancy and" exact="childhood" post="in the United Kingdom and Ireland. BMC Infect Dis2015;16:1â€&quot;11."/>
 </snippets>
</snippetsTree>
